(Q38010782)

26 August 2017

title

Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy (English)

1 reference

acute myocardial infarction

26 August 2017

0 references

1 reference

myocardial infarction

1 reference

based on heuristic

inferred from title

1 reference

3

Derek M Yellon

1 reference

26 August 2017

Vikram Sharma

1

1 reference

26 August 2017

Robert M Bell

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

Expert Opinion on Pharmacotherapy

26 August 2017

published in

1 reference

26 August 2017

volume

13

1 reference

26 August 2017

issue

8

1 reference

26 August 2017

page(s)

1153-1175

1 reference

Universal definition of myocardial infarction

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Ten year mortality in relation to original size of myocardial infarct: results from the Gothenburg metoprolol study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in coll

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Lethal "Reperfusion Injury": Is It a Real Entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Does reperfusion injury exist in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Postconditioning against ischaemia-reperfusion injury: ready for wide application in patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold-blood cardioplegia: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Remote ischaemic postconditioning protects the heart during acute myocardial infarction in pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Remote ischaemic preconditioning protects against cardiopulmonary bypass-induced tissue injury: a preclinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Postconditioning in reperfusion injury: a status report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Remote postconditioning is more potent than classic postconditioning in reducing the infarct size in anesthetized rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Remote postconditioning. Brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Oxygen-derived free radicals and postischemic myocardial reperfusion: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Introduction to the role of oxygen radicals in myocardial ischemia and infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Postconditioning in mouse hearts is inhibited by blocking the reverse mode of the sodium-calcium exchanger.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Preservation of mitochondrial function may contribute to cardioprotective effects of Na+/Ca2+ exchanger inhibitors in ischaemic/reperfused rat hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Cardiac-specific ablation of the Na+-Ca2+ exchanger confers protection against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Role of mitochondrial ion channels in cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Mitochondria and reperfusion injury of the heart--a holey death but not beyond salvation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

The inflammatory response in myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

The role of the neutrophil and free radicals in ischemic myocardial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Survival kinases in ischemic preconditioning and postconditioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

A pore way to die: the role of mitochondria in reperfusion injury and cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Targeting AMPK for cardiac protection: opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Adenosine monophosphate-activated protein kinase mediates the protective effects of ischemic preconditioning on hepatic ischemia-reperfusion injury in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

AMP-activated protein kinase mediates preconditioning in cardiomyocytes by regulating activity and trafficking of sarcolemmal ATP-sensitive K(+) channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Mitochondrial KATP opening confers protection against lethal myocardial injury and ischaemia-induced arrhythmias in the rat heart via PI3K/Akt-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Adenosine: trigger and mediator of cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Protection from ischaemic-reperfusion injury with adenosine pretreatment is reversed by inhibition of ATP sensitive potassium channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Effect of adenosine on myocardial 'stunning' in the dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Role of adenosine as adjunctive therapy in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Importance of tissue perfusion in ST segment elevation myocardial infarction patients undergoing reperfusion strategies: role of adenosine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Adenosine at reperfusion: a conundrum ready to be resolved

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Roles of mitochondrial ATP-sensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

A1 adenosine receptor overexpression attenuates ischemia-reperfusion-induced apoptosis and caspase 3 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Effect of modulating cardiac A1 adenosine receptor expression on protection with ischemic preconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Adenosine A1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Intravascular adenosine at reperfusion reduces infarct size and neutrophil adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Both A2a and A2b adenosine receptors at reperfusion are necessary to reduce infarct size in mouse hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Limitation of myocardial reperfusion injury by AMP579, an adenosine A1/A2A receptor agonist: role of A2A receptor and Erk1/2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Post-ischemic cardioprotection by A2A adenosine receptors: dependent of phosphatidylinositol 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Infarct limitation by a protein kinase G activator at reperfusion in rabbit hearts is dependent on sensitizing the heart to A2b agonists by protein kinase C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Protection from myocardial stunning by ischaemia and hypoxia with the adenosine A3 receptor agonist, IB-MECA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Exogenous adenosine triphosphate disodium administration during primary percutaneous coronary intervention reduces no-reflow and preserves left ventricular function in patients with acute anterior myocardial infarction: a study using myocardial cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery fo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

GLP-1 therapy: beyond glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Molecular basis of cardioprotection by erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study -.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After ST-Elevated Acute Myocardial Infarction (EPOC-AMI) - A Pilot, Randomized, Placebo-Controlled Study -

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

A single dose of erythropoietin in ST-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Insulin attenuates myocardial ischemia/reperfusion injury via reducing oxidative/nitrative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Glucose-insulin-potassium reduces infarct size when administered during reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Role of insulin in the anti-apoptotic effect of glucose-insulin-potassium in rabbits with acute myocardial ischemia and reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Insulin-induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

High-dose glucose-insulin-potassium treatment reduces myocardial apoptosis in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Mechanisms of atrial natriuretic peptide secretion from the atrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

The role of endothelin in mediating ischemia/hypoxia-induced atrial natriuretic peptide release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

The role of natriuretic peptides in cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Natriuretic peptide C receptor signalling in the heart and vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Preischemic infusion of alpha-human atrial natriuretic peptide elicits myoprotective effects against ischemia reperfusion in isolated rat hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Atrial natriuretic peptide reverses the negative functional effects of stunning in rabbit myocardium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Atrial natriuretic peptide protects against ischemia-reperfusion injury in the isolated rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Pravastatin attenuates lower torso ischaemia-reperfusion-induced lung injury by upregulating constitutive endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Statins and cardioprotection--more than just lipid lowering?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Effects of pretreatment with statins on infarct size in patients with acute myocardial infarction who receive fibrinolytic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Effects of administration of nicorandil or bimakalim prior to and during ischemia or reperfusion on survival rate, ischemia/reperfusion-induced arrhythmias and infarct size in anesthetized rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Preconditioning with potassium channel openers. A new concept for enhancing cardioplegic protection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Nicorandil preserves mitochondrial function during ischemia in perfused rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Noninvasive assessment of the effects of nicorandil on left ventricular volumes and function in reperfused myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Mitochondrial KATP channel activation is important in the antiarrhythmic and cardioprotective effects of non-hypotensive doses of nicorandil and cromakalim during ischemia/reperfusion: a study in an intact anesthetized rabbit model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Nicorandil and leukocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Nicorandil protects cardiac mitochondria against permeability transition induced by ischemia-reperfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Effect of intra-coronary nicorandil administration prior to reperfusion in acute ST segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Cyclosporine A limits myocardial infarct size even when administered after onset of ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Cyclosporine A prevents apoptosis-related mitochondrial dysfunction after neonatal cardioplegic arrest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Cardioprotective effects of cyclosporine A in an in vivo model of myocardial ischemia and reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Effect of cyclosporine on reperfusion injury in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

High-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

Pharmacological prevention of reperfusion injury in acute myocardial infarction. A potential role for adenosine as a therapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685163

10.1517/14656566.2012.685163

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference